Cargando…
Osteomalacia in an HIV-infected man receiving rifabutin, a cytochrome P450 enzyme inducer: a case report
INTRODUCTION: People infected with human immunodeficiency virus are frequently treated with medications that can induce or inhibit cytochrome P450 enzymes. CASE PRESENTATION: A 59 year old man treated with zidovudine, lamivudine, indinavir, and ritonavir for infection with human immunodeficiency vir...
Autores principales: | Bolland, Mark J, Grey, Andrew, Horne, Anne M, Thomas, Mark G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2253556/ https://www.ncbi.nlm.nih.gov/pubmed/18226256 http://dx.doi.org/10.1186/1476-0711-7-3 |
Ejemplares similares
-
Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
por: Moultrie, Harry, et al.
Publicado: (2015) -
Structure and function of the cytochrome P450 peroxygenase enzymes
por: Munro, Andrew W., et al.
Publicado: (2018) -
Allosteric modulation of cytochrome P450 enzymes by the NADPH cytochrome P450 reductase FMN-containing domain
por: Burris-Hiday, Sarah D., et al.
Publicado: (2023) -
Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine
por: Lutz, Justin D., et al.
Publicado: (2018) -
Enzyme Activity of Natural Products on Cytochrome P450
por: Zuo, Hua-Li, et al.
Publicado: (2022)